Eli Lilly In Trouble Over Cialis Ads
The manufacturer of the impotence medication Cialis is to get a strong reprimand from the pharmaceutical industry watchdog in the United Kingdom for 'unbalanced' promotion of its anti-erectile dysfunction drug Cialis, in violation of ethical rules. The Prescription Medicines Code of Practice Authority issued a statement saying that Eli Lilly had brought discredit on the pharmaceutical industry through a marketing campaign on television, the internet and in brochures in GP surgeries in the UK.
The Lilly campaign that is the focus of this reprimand is the so-called "40 over 40" campaign, which claims that "40 per cent of men aged over 40 had problems with erectile dysfunction."
The PMCPA said that Eli Lilly had published information about Cialis which did not explain the risks and side effects associated with using the impotence medication, and this would have encouraged men to get a prescription for Cialis without knowing enough about it.
Eli Lilly has toned down its promotion of the Cialis drug and the '40 over 40' campaign in response to this judgment and has accepted the ruling. In fact Eli Lilly agreed to stop using certain parts of its advertising campaign last month after concerns were raised by health officials. Direct-to-consumer advertising for prescription medication is not allowed in the United Kingdom however drug companies are allowed to provide information about illnesses and where to get help for them. In America prescription medications are allowed to be advertised subject to various rules and regulations.
Similar Posts:
- Pfizer Developing New Viagra Ad: After the FDA ordered Pfizer to pull its Viagra ads in 2004, the drugmaker is now shifting to PR campaigns focusing on disease awareness.
- Do I Need a Prior Prescription to Buy Viagra?: Find out if you can buy Viagra without a prescription . Is it safe? always think about your health before you save a few dollars on cheap Viagra that might not have even been produced in the United States
- Eli Lilly 'surprised' by Swiss fine: The Swiss branches of Eli Lilly and Co., Pfizer and Bayer were fined a total of $5.7 million by regulators for fixing the price of erectile dysfunction drugs.